Back to Search
Start Over
Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency
- Source :
- British Journal of Clinical Pharmacology, British Journal of Clinical Pharmacology, 2022, Global Pharmacovigilance, 89 (5), pp.762-772. ⟨10.1111/bcp.15536⟩, British journal of clinical pharmacology, Vol. 89, no.2, p. 762-772 (2023), British Journal of Clinical Pharmacology, 2022, ⟨10.1111/bcp.15536⟩
- Publication Year :
- 2022
- Publisher :
- HAL CCSD, 2022.
-
Abstract
- International audience; AIMS: Determining dihydropyrimidine dehydrogenase (DPD) activity by measuring patient’s uracil (U) plasma concentration is mandatory before fluoropyrimidines (FP) administration in France. In this study, we aimed to refine the pre-analytical recommendations for determining U and dihydrouracil (UH(2) ) concentrations, since they are essential in reliable DPD deficiency testing.METHODS: U and UH(2) concentrations were collected from 14 hospital laboratories. Stability in whole blood and plasma after centrifugation, the type of anticoagulant and long-term plasma storage were evaluated. The variation induced by time and temperature was calculated and compared to an acceptability range of ± 20%. Inter-occasion variability (IOV) of U and UH(2) was assessed in 573 patients double sampled for DPD-deficiency testing. RESULTS: Storage of blood samples before centrifugation at room temperature (RT) should not exceed 1 h, whereas cold (+4°C) storage maintains U stable after 5 hours. For patients correctly double sampled, IOV of U reached 22.4% for U (SD = 17.9%, range = [0-99%]). Notably, 17% of them were assigned with a different phenotype (normal or DPD deficient) based on the analysis of their two samples. For those having at least one non-compliant sample, this percentage increased up to 33.8%. The moment of blood collection did not affect the DPD phenotyping result.CONCLUSION: Caution should be taken when interpreting U concentrations if the time before centrifugation exceeds 1 h at RT, since it rises significantly afterwards. Not respecting the pre-analytical conditions for DPD phenotyping increases the risk of DPD status misclassification.
- Subjects :
- Pharmacology
Dihydropyrimidine Dehydrogenase Deficiency
[SDV]Life Sciences [q-bio]
dihydropyrimidine dehydrogenase
[SDV.CAN]Life Sciences [q-bio]/Cancer
Plasma
Phenotype
intra-individual variability
[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology
Humans
Pharmacology (medical)
uracil
Fluorouracil
pre-analytical practices
[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM]
dihydrouracil
Dihydrouracil Dehydrogenase (NADP)
Subjects
Details
- Language :
- English
- ISSN :
- 03065251 and 13652125
- Database :
- OpenAIRE
- Journal :
- British Journal of Clinical Pharmacology, British Journal of Clinical Pharmacology, 2022, Global Pharmacovigilance, 89 (5), pp.762-772. ⟨10.1111/bcp.15536⟩, British journal of clinical pharmacology, Vol. 89, no.2, p. 762-772 (2023), British Journal of Clinical Pharmacology, 2022, ⟨10.1111/bcp.15536⟩
- Accession number :
- edsair.doi.dedup.....80af44c84ce11ab9d7816852e6142b67
- Full Text :
- https://doi.org/10.1111/bcp.15536⟩